The FDA's drug approvals database lists a supplement, dated 2 October 2026, to a generic clozapine abbreviated new drug application held by Mylan. The listing gives no clinical detail, and supplements to generic applications usually cover manufacturing, labelling alignment or packaging rather than new safety findings.
Nothing in this record changes how clozapine is prescribed or monitored. If your pharmacy stocks this supplier's product, check that the current package insert is the one in use.
- No change to clozapine prescribing or monitoring follows from this supplement.
- Check your pharmacy holds the current package insert for this supplier's clozapine.
- Continue your local neutrophil monitoring protocol for clozapine as before.
- Treat any brand or supplier switch as a moment to recheck the patient's clozapine level if clinically indicated.
Why it matters
Regulatory activity on an established drug is usually paperwork, and reading it that way avoids needless changes.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free